NICE backs Braftovi for BRAF-positive colorectal cancer
Positive recommendation follows initial rejection in September
Read More
Tag: Pierre Fabre
NICE no for Pierre Fabre’s Braftovi
Preliminary guidelines reject NHS funding for the drug for BRAF V600E mutation-positive metastatic colorectal cancer
Read More
EU nod for new metastatic colorectal cancer combination
Pierre Fabre’s Braftovi in combination with Erbitux is the first licensed therapy for a specific subset of colorectal cancer patients
Read More
HSE reimburses Braftovi combo
Eligible patients in the Republic of Ireland can potentially benefit from the combination with immediate effect.
Read More
New early breast cancer option recommended by NICE
The drug is recommended provided that Herceptin (trastuzumab) is the only HER2-directed adjuvant treatment people have had.
Read More
EU approves new option for metastatic melanoma
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
Read More
Four pharmas named for breaching ABPI Code of Practice
Martindale Pharma, Pierre Fabre, Janssen and Pharmasure have all been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s Code of Practice.
Read More
FDA approves Pierre Fabre/Array Biotech melanoma combo
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.
Read More
Pierre Fabre, Array showcase potential of triple therapy for CRC
Pierre Fabre and Array BioPharma have unveiled data from a late-stage trial showing a significant improvement in one-year survival in colorectal cancer patients taking encorafenib, binimetinib and cetuximab versus the standard of care.
Read More
Pharma firms fall foul of ABPI Code
Vifor Pharma, Celgene, Takeda and Pierre Fabre have been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice thus bringing discredit upon and reducing confidence in the sector.
Read More
Merck links with Array, Pierre Fabre to test cancer combo
Germany’s Merck has linked with Array BioPharma and Pierre Fabre to initiate a lage-stage trial assessing the efficacy of a new combination therapy in BRAF-mutant metastatic colorectal cancer.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
